PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann Oxford, United Kingdom “ 8th April 2024 “ OMass Therapeutics (˜OMass™ or ˜the Company™), a...
PRESS RELEASE OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer Oxford, United Kingdom “ 15 November 2023 “ OMass Therapeutics (˜OMass™ or...
PRESS RELEASE OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board Oxford, United Kingdom “ 26th September 2023 “ OMass Therapeutics (˜OMass™ or ˜the Company™), a biotechnology...
PRESS RELEASE OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created rolesPeter Phillips M.D., Ph.D. joins as Senior Vice...
PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from...
OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress
Oxford, United Kingdom – 10 November 2022 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines against highly validated target ecosystems, today highlights the potential benefits of native mass spectrometry (MS) in drug discovery through its new publication “Mass spectrometry captures biased signalling and allosteric modulation of the ?1 adrenergic receptor” published today in Nature Chemistry1.
PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi...
PRESS RELEASE OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysical Approaches to Drug Discovery Oxford, United Kingdom – 7 March 2022 – OMass Therapeutics...
PRESS RELEASE OMass's OdyssION Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D Oxford, United Kingdom – 28 February 2022 – OMass Therapeutics (‘OMass’ or...